Gideon Capital Advisors’s ResMed RMD Stock Holding History

Gideon Capital Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,094	Closed	-$242K	–	490
2018 Q3	$242K	Sell	2,094 -903	-30%	-$98.9K	0.11%	282
2018 Q2	$310K	Buy	+2,997	New	+$303K	0.16%	251
2018 Q1	–	Sell	-3,541	Closed	-$300K	–	446
2017 Q4	$300K	Buy	+3,541	New	+$293K	0.26%	166

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gideon Capital Advisors's RMD Position: Q4 2018 in Review

Gideon Capital Advisors sold out of ResMed (RMD) in Q4 2018, closing a stake of 2,094 shares — an estimated $242K sold.

Gideon Capital Advisors first reported a position in RMD in Q4 2017 and held it in 3 quarters. The position peaked at $310K in Q2 2018. 501 funds tracked by Wall St. Rank hold RMD as of Q4 2018.

Gideon Capital Advisors reported no remaining ResMed position as of Q4 2018 after selling out during the quarter.
Gideon Capital Advisors sold 2,094 ResMed shares in Q4 2018, an estimated $242K.
Gideon Capital Advisors first reported a position in ResMed in Q4 2017 and held it in 3 quarters.
Gideon Capital Advisors's ResMed position peaked at $310K in Q2 2018.
501 funds tracked by Wall St. Rank held ResMed as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.